NeoFlow
Endovascular Solution for Vasospasm in Aneurysmal Subarachnoid Hemorrhage
Company Overview
Snapshot
Founded in January 2023 by David Skorohod, Maroun Farah, and Limor Sandach, NeoFlow operates with 1–10 employees. The company secured its Pre-Seed funding round in January 2023 from NGT HealthCare II.
Business overview
NeoFlow Technologies is developing novel endovascular solutions for the treatment of vasospasm in Aneurysmal Subarachnoid Hemorrhage (aSAH). This critical condition often leads to Delayed Ischemic Neurological Deficit (DIND) in approximately 40% of cases. The company aims to create a widely accessible, simple-design endovascular device to achieve vasoconstriction relief through local manipulation, thereby reducing the risks associated with traditional balloon angioplasty and systemic pharmacological treatments. NeoFlow operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers.
Log in to access full profile ›Company Intelligence Q&A
- What is NeoFlow's primary focus?
- NeoFlow focuses on developing novel endovascular solutions for treating vasospasm in Aneurysmal Subarachnoid Hemorrhage (aSAH), a major complication leading to Delayed Ischemic Neurological Deficit (DIND).
- When was NeoFlow founded?
- NeoFlow was founded in January 2023.
- Who are the founders of NeoFlow?
- The co-founders of NeoFlow are David Skorohod, Maroun Farah, and Limor Sandach.
- What is the current status of NeoFlow?
- NeoFlow is currently non-active and ceased to operate in September 2025.
- Which investor participated in NeoFlow's Pre-Seed funding round?
- In January 2023, NeoFlow secured Pre-Seed funding from NGT HealthCare II.